Clinical trial · Interventional
Effect of GTx-758 on Total and Free Testosterone Levels in Men With Prostate Cancer
Phase II, Open Label, Dose Finding Study of the Effect of GTx-758 on Total and Free Testosterone Levels in Men With Prostate Cancer Compared to a Luteinizing Hormone Releasing Hormone Agonist
NCT01326312CI-TRIAL-00067396GTx758terminatedPhase 2Results postedClinicalTrials.gov clinicaltrialsProvenance
- Source
- ClinicalTrials.gov
- Retrieved
- Sep 8, 2026
- Layer
- normalized (units and labels harmonized; values unchanged)
- Run
- ING-CLINICALTRIALS-20260908-000001
Why stopped (as posted): FDA Clinical Hold
Summary
Brief summary (as posted)
The purpose of this study is to determine whether GTx 758 is effective in achieving and maintaining castrate testosterone levels in men with advanced prostate cancer.
Conditions
Conditions (1)
Free-text conditions as registered, with the CancerIndex entity they were reconciled to and the match type.
| Condition (as posted) | Mapped entity | Match | Confidence |
|---|---|---|---|
| Prostate Cancer | Malignant Prostate Neoplasm | CURATED_EXACT | 0.92 |
Interventions
Interventions (3)
| Intervention | Type | Mapped drug | Match |
|---|---|---|---|
| GTx-758 1000mg | Drug | — | UNRESOLVED |
| GTx-758 2000mg | Drug | — | UNRESOLVED |
| Lupron Depot | Drug | Leuprolide | ALIAS |
Design
Arms and outcomes
Arms (3)
- type
- EXPERIMENTAL
- label
- GTx- 758 1000mg
- description
- GTx-758/Experimental/ nonsteroidal selective ER alpha agonist
- interventionNames
- Drug: GTx-758 2000mg
- type
- EXPERIMENTAL
- label
- GTx-758 2000mg
- description
- GTx-758/Experimental/ nonsteroidal selective ER alpha agonist
- interventionNames
- Drug: GTx-758 1000mg
- type
- ACTIVE_COMPARATOR
- label
- Lupron Depot
- description
- Luteinizing Hormone Releasing Hormone Agonist
Eligibility
Eligibility (as posted)
- Sex
- Male
- Minimum age
- 45 Years
- Maximum age
- 80 Years
Show eligibility criteria text
Inclusion Criteria: 1. be between age 45 and 80 years of age 2. be able to communicate effectively with study personnel 3. ECOG is \< or = 2 4. screening serum total testosterone\> or = 150ng/dL 5. have prostate cancer, confirmed by pathology report 6. have not been treated with androgen deprivation therapy(chemical or surgical 7. have a clinical indication for the initiation of androgen deprivation therapy 8. give written informed consent prior to any study specific procedures 9. subject must agree to use acceptable methods of contraception Exclusion Criteria: 1. known hypersensitivity or allergy to estrogen or estrogen like drugs 2. a clinically significant concurrent illness or psychological, familial, sociological, geographical or other concomitant condition that would not permit adequate follow-up and compliance with the study protocol 3. history of abnormal blood clotting,Factor V Leiden clotting disorder, thrombotic disease 4. have ALT or AST above 2 times the upper normal limit 5. have alkaline phosphatase greater than 3 times UNL and/or bilirubin levels above 2mg/dL at baseline 6. patients cannot have brain or spinal cord metastases 7. patients cannot have or be at risk for spinal cord compression from bone metastases 8. received an investigational drug within a period of 90 days prior to enrollment in the study 9. received the study medication previously 10. currently taking testosterone, testosterone-like agents, or antiandrogens including 5-alpha reductase inhibitors within 4 weeks of randomization 11. currently taking Saw Palmetto or PC-SPES (the subject may be considered for randomization after a 4 week washout period prior to randomization) 12. have taken diethylstilbestrol or other estrogen products within the previous 12 months prior to randomization 13. have taken body building or fertility supplements within 4 weeks of admission into the study (steroids and steroid like supplements) 14. have a history of cancer other than prostate cancer, superficial bladder cancer (with no recurrence in the last 5 years) and/or non-melanoma carcinoma of the skin 15. QTcB\>480 msec, If the first QTcB reading exceeds 480msec two additional ECGs are to be performed separated at least 5 min apart, then take the average of the three QTcB or readings to determine if the subject satisfies the above criteria. If the average QYcB reading is \>480 msec then the subject is excluded.
References
Publications (0)
Data not yet available
No reference posted for this study.